Skip to main content
Top
Published in: Advances in Therapy 9/2020

01-09-2020 | Bronchial Asthma | Commentary

Global Quality Standard for Identification and Management of Severe Asthma

Authors: John Haughney, Tonya A. Winders, Steve Holmes, Pascal Chanez, Hannah Saul, Andrew Menzies-Gow, the PRECISION Improve Access to Better Care Task Force

Published in: Advances in Therapy | Issue 9/2020

Login to get access

Abstract

Introduction

Severe asthma is a debilitating, life-threatening disease associated with substantial global morbidity, mortality, and health care resource utilization. Patients may not receive guideline-directed medical care for severe asthma. Moreover, viable precision-based assessment tools and newer preventive therapies that can reduce the frequency of exacerbations and associated functional impact are underused. As a result, high rates of poorly controlled severe asthma persist, and patient health-related quality of life suffers.

Methods

In 2019, the Improve Access to Better Care Task Force of the PRECISION Steering Committee set out to develop a global template on quality standards for severe asthma care to support improved access to and delivery of quality care. This Quality Standard is grounded in the vast body of published evidence available for severe asthma care, published clinical guidelines (i.e., from the Global Initiative for Asthma in 2019 and the European Respiratory Society/American Thoracic Society in 2014), and the 2018 PRECISION-supported Charter to Improve Patient Care in Severe Asthma.

Results

The Quality Standard developed emphasizes four key elements aimed at optimizing clinical care and outcomes in severe asthma: (1) organization of services, (2) timely identification and referral for suspected severe asthma, (3) specialized assessment and management of severe asthma to optimize outcomes, and (4) patient-centric care and shared decision-making that is reflective of the patient’s expectations, priorities, and values. Four key Quality Statements are provided, along with quality metrics and strategies for local adaptation to optimize implementation.

Conclusion

This Global Quality Standard is intended to mobilize policymakers, health care providers, and patient advocacy groups to build consensus on the definition and expectations of quality care in severe asthma, to promote patient-centric care, to identify gaps in care and areas for improvement, and systematically implement improvement measures and outcomes and to reduce the burden of illness for patients with severe asthma.
Literature
2.
go back to reference Vos T, Abajobir AA, Abate KH, et al. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRef Vos T, Abajobir AA, Abate KH, et al. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRef
3.
go back to reference Hay SI, Abajobir AA, Abate KH, et al. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1260–344.CrossRef Hay SI, Abajobir AA, Abate KH, et al. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1260–344.CrossRef
5.
go back to reference D’Amato G, Vitale C, Molina A, et al. Asthma-related deaths. Multidiscip Respir Med. 2016;11:37.CrossRef D’Amato G, Vitale C, Molina A, et al. Asthma-related deaths. Multidiscip Respir Med. 2016;11:37.CrossRef
6.
go back to reference Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209–23.CrossRef Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209–23.CrossRef
8.
go back to reference Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet. 2005;365(9463):974–6.CrossRef Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet. 2005;365(9463):974–6.CrossRef
9.
11.
go back to reference Tran TN, King E, Sarkar R, et al. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy, and the UK. Eur Respir J. 2020;55(6):1902363.CrossRef Tran TN, King E, Sarkar R, et al. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy, and the UK. Eur Respir J. 2020;55(6):1902363.CrossRef
12.
go back to reference Bhandori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.CrossRef Bhandori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.CrossRef
13.
go back to reference Menzies-Gow A, Canonica GW, Winders TA, Correia Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35:1485–96.CrossRef Menzies-Gow A, Canonica GW, Winders TA, Correia Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35:1485–96.CrossRef
14.
go back to reference Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRef Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRef
15.
go back to reference Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1):1701126.CrossRef Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1):1701126.CrossRef
16.
go back to reference Merchant RK, Inamdar R, Quade RC. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract. 2016;4(3):455–63.CrossRef Merchant RK, Inamdar R, Quade RC. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract. 2016;4(3):455–63.CrossRef
Metadata
Title
Global Quality Standard for Identification and Management of Severe Asthma
Authors
John Haughney
Tonya A. Winders
Steve Holmes
Pascal Chanez
Hannah Saul
Andrew Menzies-Gow
the PRECISION Improve Access to Better Care Task Force
Publication date
01-09-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 9/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01450-7

Other articles of this Issue 9/2020

Advances in Therapy 9/2020 Go to the issue